The table below shows Stoke Therapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q3 2025
Q2 2025
Q1 2025
Q3 2024
Q2 2024
Revenue
$6.23M
$10.63M
$13.82M
$158.57M
$4.89M
$4.83M
Cost of revenue
-
-
-
-
-
-
Gross profit
-
-
-
-
-
-
R&D
$39.67M
$37.70M
$25.86M
$32.68M
$22.20M
$21.14M
SG&A
STOK annual revenue (10-K history)
Stoke Therapeutics, Inc. reported annual revenue of $184.42M for fiscal year 2025. That is up 404.5% from $36.55M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.